Polatuzumab vedotin-piiq (Polivy®) against CD79b with an enzymatically cleavable linker, approved for blood cancer in 2019, entered cells and released a potent cytotoxic agent, MMAE, into the cytoplasm after lysosomal escape via passive diffusion [27]. The gene discussed is CD79B; the disease is hematopoietic and lymphoid system neoplasm.